BIOLIFE SOLUTIONS INC(BLFS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

BIOLIFE SOLUTIONS INC (BLFS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BLFS at 62.1/100 on a 32-signal composite quality model, placing it at rank #732 of 2,962 stocks — the top 25% of the AI-ranked universe. BLFS scores in the top quartile across profitability (98.3), balance sheet strength (91.6), revenue growth (75.8). Areas of concern include revenue scale (16.8) and institutional flow (22.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 7.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), BIOLIFE SOLUTIONS INC reports quarterly revenue of $28.5M, net income of $45.1M, an operating margin of 6.0%. Top institutional holders of BLFS by reported 13-F value include T. Rowe Price Investment Management, BlackRock, Casdin Capital, based on the most recent SEC filings. BLFS trades on the Nasdaq exchange and files with the SEC under CIK 834365. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BLFS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BIOLIFE SOLUTIONS INC directly from SEC EDGAR.